Published Paper Details:

The regulatory landscape for medical devices in the United States has undergone a profound transformation with the U.S. Food and Drug Administration's (FDA) issuance of the Quality Management System Regulation (QMSR) final rule on February 2, 2024. This rule, effective February 2, 2026, fundamentally overhauls the longstanding Quality System Regulation (QSR) under 21 CFR Part 820 by incorporating the International Organization for Standardization (ISO) 13485:2016 standard by reference. Designed to foster global harmonization, the QMSR aligns U.S. current good manufacturing practices (CGMP) with international benchmarks, alleviating compliance redundancies for manufacturers operating in multifaceted markets. This shift emphasizes the integration of risk management, lifecycle oversight, and interdisciplinary pharmacology into device governance. Drawing on the FDA's economic analysis, the QMSR is projected to yield annualized net cost savings of $532 million at a 7% discount rate, while enhancing device safety and accelerating market access. This review delineates the historical evolution, core amendments, transitional hurdles, case studies, global comparisons, and pedagogical value of the QMSR, underscoring its role in elevating patient-centric innovation amid evolving pharmaco-regulatory paradigms. As of September 2025, with the transition period underway, manufacturers are urged to conduct gap analyses to mitigate risks.